Biocon Ltd

About

Biocon is a pharmaceutical company founded in India with a major aim to find ways to treat cancer, diabetes, and autoimmune diseases. Its 4 primary business verticals—generics, biosimilars, novel biologics, and biosimilars—are present in more than 120 countries all over the world. Biocon co-develops insulin analogues and biosimilar antibodies in partnership with Viatris. Its partnership with Sandoz, a Novartis division, assists in the production of biosimilars for oncology and immunology. The company has also formed an alliance with Serum Institute Life Sciences (SILS) to develop vaccines and antibodies against infectious diseases. Its production of ADG20, an antibody working against the spike protein of the coronavirus, in partnership with Adagio Therapeutics of the US, was influential in keeping the COVID rise in check. Though headquartered in Bangalore, Biocon operates through offices in locations like the US, UK, Ireland, Greece, and Malaysia internationally.